검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Pemigatinib |
Overview Company | Fondazione per la Medicina Personalizzata |
Overview Modality | ADC |
Overview Target | Breast Cancer |
Overview Indication | Breast Cancer; Gastrointestinal Cancer |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
MoA Mechanism | targeting subtype-specific pathway |
MoA Biomarker | biomarkers and effective therapeutic targets |
PK/PD Species | Rat, ration, induced apoptosis in vitro, and significantly reduced xenograft |
PK/PD Animal (cat.) | Rat, In vitro |
PK/PD Experiment | PK |
Toxicology Species | Rat, ration, induced apoptosis in vitro, and significantly reduced xenograft |
Toxicology Animal (cat.) | Rat, In vitro |
Toxicology Major finding | Calciphylaxis as a Rare Complication Associated with Pemigatinib Treatment-A Case Report.. Fibroblast growth factor receptor 2 (FGFR2) inhibitors such as pemigatinib are targeted therapies for cholangiocarcinoma with FGFR2 alterations. While generally well tolerated, they are associated with unique adverse events. Calciphylaxis, a potentially fatal vascular calcification disorder, is a rare compli… |
Clinical Primary efficacy | ORR 37% |
Clinical ORR | 0.0% |
Clinical PFS | 7.03 |
Clinical OS | 17.48 |
Clinical Result source | ClinicalTrials.gov NCT02924376 |
Clinical Data Tier / Score | A · 52 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Pemigatinib |
Overview Company | Fondazione per la Medicina Personalizzata |
Overview Modality | ADC |
Overview Target | Breast Cancer |
Overview Indication | Breast Cancer; Gastrointestinal Cancer |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
MoA Mechanism | targeting subtype-specific pathway |
MoA Biomarker | biomarkers and effective therapeutic targets |
PK/PD Species | Rat, ration, induced apoptosis in vitro, and significantly reduced xenograft |
PK/PD Animal (cat.) | Rat, In vitro |
PK/PD Experiment | PK |
Toxicology Species | Rat, ration, induced apoptosis in vitro, and significantly reduced xenograft |
Toxicology Animal (cat.) | Rat, In vitro |
Toxicology Major finding | Calciphylaxis as a Rare Complication Associated with Pemigatinib Treatment-A Case Report.. Fibroblast growth factor receptor 2 (FGFR2) inhibitors such as pemigatinib are targeted therapies for cholangiocarcinoma with FGFR2 alterations. While generally well tolerated, they are associated with unique adverse events. Calciphylaxis, a potentially fatal vascular calcification disorder, is a rare compli… |
Clinical Primary efficacy | ORR 37% |
Clinical ORR | 0.0% |
Clinical PFS | 7.03 |
Clinical OS | 17.48 |
Clinical Result source | ClinicalTrials.gov NCT02924376 |
Clinical Data Tier / Score | A · 52 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
추천 비교
추천 비교